Welcome to our dedicated page for ESSA Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on ESSA Pharma stock.
ESSA Pharma Inc. (NASDAQ: EPIX) is a clinical-stage pharmaceutical company dedicated to advancing novel therapeutics for cancer patients, specifically those battling castration-resistant prostate cancer (CRPC). Founded on cutting-edge research, ESSA Pharma is pioneering the development of small molecule drugs that selectively target the amino-terminal domain of the androgen receptor. This innovative approach aims to overcome known AR-dependent resistance mechanisms in CRPC, potentially offering improved progression-free and overall survival for patients.
ESSA Pharma's flagship candidate, Masofaniten (formerly EPI-7386), is a first-in-class N-terminal domain androgen receptor (AR) inhibitor. Additionally, the company has demonstrated promising results in Phase 1/2 clinical trials that combine Masofaniten with Enzalutamide, another AR inhibitor. These trials have shown deep, durable reductions in prostate-specific antigen (PSA) levels, which are crucial markers in prostate cancer treatment.
Recent data presented at the European Society of Medical Oncology (ESMO) 2023 Congress and the Prostate Cancer Foundation Scientific Retreat reveal that the combination therapy of Masofaniten and Enzalutamide is well-tolerated and effective in reducing PSA levels in patients with metastatic CRPC. The randomized Phase 2 dose expansion study is currently enrolling, with the goal of further elucidating the clinical benefits of this combination therapy.
In recent developments, ESSA Pharma has entered into an ATM Sales Agreement with Jefferies LLC to raise up to US$50 million in capital, ensuring a strong financial runway for ongoing and future projects. The company also reported encouraging financial results for the fiscal year ended September 30, 2023, and the fiscal first quarter of 2024, reflecting a robust cash position expected to fund operations through 2025.
ESSA Pharma's strategy includes exploring additional combinations of Masofaniten with other standard-of-care antiandrogens. The U.S. Food and Drug Administration has granted Fast Track designation to Masofaniten for the treatment of adult male patients with mCRPC resistant to standard-of-care treatments, underscoring the potential importance of this therapy.
For more information, visit the company’s website at www.essapharma.com, or follow them on Twitter and LinkedIn.
ESSA Pharma Inc. (NASDAQ: EPIX) announced participation in three virtual investor conferences on November 8, 2021. David R. Parkinson, President and CEO, along with COO Peter Virsik and CFO David S. Wood, will host one-on-one meetings. The events include the Jefferies London Healthcare Conference on November 18, Piper Sandler 33rd Annual Healthcare Conference on November 22, and Evercore ISI HealthCONx Conference on December 2. Webcasts will be available on ESSA's website for 90 days post-event.
ESSA Pharma Inc. (NASDAQ: EPIX) presented preclinical data on EPI-7386, a leading prostate cancer treatment, at the 2021 Prostate Cancer Foundation Scientific Retreat on October 28-29, 2021. The data confirm EPI-7386's binding to the N-terminal domain of the androgen receptor, a region not targeted by existing therapies. The compound is undergoing a Phase 1 clinical trial for metastatic castration-resistant prostate cancer (mCRPC) and has received Fast Track designation from the U.S. FDA. Additional details are available on ESSA's website.
ESSA Pharma Inc. (NASDAQ: EPIX) presented preclinical data on EPI-7386, a novel androgen receptor N-terminal domain inhibitor for prostate cancer treatment, at the 2021 AACR-NCI-EORTC Virtual Conference. The studies demonstrate EPI-7386's binding mechanism to the androgen receptor's N-terminal domain, confirming its unique anti-cancer activity. The data also indicate that EPI-7386 can inhibit AR-driven biology, including AR splice variant activity. The company plans to initiate Phase 1/2 combination trials with antiandrogens for metastatic castration-resistant prostate cancer.
ESSA Pharma Inc. (Nasdaq: EPIX) and Caris Life Sciences have launched a Precision Development program aimed at enhancing the clinical trial for EPI-7386, a treatment for metastatic castration-resistant prostate cancer (mCRPC). The collaboration will utilize Caris' Whole Transcriptome and Whole Exome Sequencing technologies to analyze patient blood samples, enabling better characterization of tumor profiles. This partnership is expected to identify specific patient tumor biological subpopulations, potentially improving the efficiency of EPI-7386 development.
ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company dedicated to prostate cancer treatments, announces that CEO David R. Parkinson will present at two upcoming virtual investor conferences. Key details include the H.C. Wainwright Annual Global Investment Conference on September 13, 2021, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, 2021. Investors can access webcasts on ESSA's website, with archives available for 90 days post-event.
ESSA Pharma Inc. (NASDAQ: EPIX) announced a corporate update alongside its fiscal Q3 2021 financial results. For the quarter ended June 30, 2021, the company reported a net loss of $8.8 million, compared to $4.9 million in the same quarter of 2020. The increase in losses reflects higher R&D expenditures of $6.2 million due to ongoing Phase 1a clinical trials for EPI-7386, a novel therapy for metastatic castration-resistant prostate cancer (mCRPC). ESSA's cash reserves stand at $202 million, offering a runway into 2024 as it advances clinical trials and collaborations.
ESSA Pharma Inc. (Nasdaq: EPIX) announced that CEO David R. Parkinson will participate in a fireside chat at the Jefferies Virtual Healthcare Conference from June 1 to June 4, 2021. The chat is scheduled for June 1 at 1:30 PM ET. Alongside Dr. Parkinson, COO Peter Virsik and CFO David S. Wood will be available for one-on-one meetings. A webcast of the event will be accessible via ESSA's website and archived for 90 days. ESSA focuses on developing novel therapies for prostate cancer.
ESSA Pharma Inc. (NASDAQ: EPIX) provided an update on its progress and financial results for the second quarter ending March 31, 2021.
Key highlights include promising pharmacokinetic data on EPI-7386 in metastatic castration-resistant prostate cancer (mCRPC) and a successful public offering raising approximately $150 million to fund ongoing studies and R&D efforts.
The company reported a net loss of $13 million for the quarter, up from a $9.4 million loss in Q2 2020, with total cash reserves reaching $208.6 million.
ESSA Pharma Inc. (Nasdaq: EPIX) announced a collaboration with Bayer to evaluate EPI-7386, an N-terminal domain androgen receptor inhibitor, in a Phase 1/2 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial will assess the efficacy and safety of combining EPI-7386 with Bayer's darolutamide. ESSA will supply EPI-7386 and retains all rights to the drug. The study is set to start in 2021, with EPI-7386 having already received Fast Track designation from the U.S. FDA.
ESSA Pharma Inc. (Nasdaq: EPIX) announced that CEO Dr. David R. Parkinson will present at the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 11:00 AM ET. The presentation will last 30 minutes and include a Q&A session. Dr. Parkinson, COO Peter Virsik, and CFO David S. Wood will also hold one-on-one meetings. Attendees can access the presentation via a webcast on ESSA's website, available for 90 days post-event. The conference aims to update investors on developments within the Canadian healthcare sector.
FAQ
What is the current stock price of ESSA Pharma (EPIX)?
What is the market cap of ESSA Pharma (EPIX)?
What is ESSA Pharma Inc. focused on?
What is Masofaniten?
What recent achievements has ESSA Pharma reported?
What is the significance of the Phase 1/2 clinical trials?
What are the future plans for ESSA Pharma?
What financial position is ESSA Pharma in?
What designations has Masofaniten received from regulatory authorities?
Where can I find more information about ESSA Pharma?
How does Masofaniten work?
What partnerships does ESSA Pharma have?
